title: Cerebellar and thalamic metabolic changes visualized by [18]-FDG-PET in olanzapine-induced acute akathisia.
abstract: OBJECTIVE
  Akathisia is a clinical important symptom, frequently induced by neuroleptic treatment. Despite its clinical importance, less is known about its pathophysiology.
  
  
  METHODS
  Using [18]-FDG-PET, imaging patterns of cortical metabolic activity were obtained in a patient during olanzapine-induced akathisia and after recovery.
  
  
  RESULTS
  Akathisia was characterized by a reduced metabolic activity in thalamus and cerebellum. After discontinuing medication akathisia disappeared, reflected by a recovery of metabolic activity in these brain areas.
  
  
  CONCLUSIONS
  [18]-FDG-PET may be useful to identify cortical regions mediating clinical aspects of drug-induced akathisia, thereby offering a deeper insight into the pathophysiology of this serious side effect.
authors.affiliation: Department of Psychiatry, Psychosomatics and Psychotherapy, University of Regensburg, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Landgrebe
authors.forename: Jörg
authors.initials: J
authors.lastname: Marienhagen
authors.forename: Berthold
authors.initials: B
authors.lastname: Langguth
authors.forename: Philipp
authors.initials: P
authors.lastname: Sand
authors.forename: Peter
authors.initials: P
authors.lastname: Eichhammer
authors.forename: Göran
authors.initials: G
authors.lastname: Hajak
mesh_terms: D000208:Acute Disease; D017109:Akathisia, Drug-Induced / Q000000981:diagnostic imaging* / Q000378:metabolism; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D002531:Cerebellum / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D049268:Positron-Emission Tomography / Q000379:methods; D019275:Radiopharmaceuticals; D012559:Schizophrenia / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy; D013788:Thalamus / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism
chemical_list: D014150:Antipsychotic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D001569:Benzodiazepines; D000077152:Olanzapine